Preclinical Evaluation of a Cross-Protective ß-SARS-CoV-2 Virus-Like Particle Vaccine Adjuvanted with MF59
Linda Earnest(The University of Melbourne), Joseph Torresi(The University of Melbourne), Daniel Fernandez‐Ruiz(UNSW Sydney), Samantha L. Grimley(The University of Melbourne), William R. Heath(Peter Doherty Institute), Lauren E. Holz(The University of Melbourne), Melissa A. Edeling(The University of Melbourne), Lin‐Fa Wang(Beijing Institute of Technology), Jamie Mumford(Duke-NUS Medical School), Elizabeth Vincan(The University of Melbourne), Marc Pellegrini(The University of Melbourne), Dale I. Godfrey(Peter Doherty Institute), Kanta Subbarao(Peter Doherty Institute), James P. Cooney(The University of Melbourne), Danielle E. Anderson(Peter Doherty Institute), Jason M. Mackenzie(Peter Doherty Institute), Dhiraj Hans(International Centre for Genetic Engineering and Biotechnology), Stéphanie Gras(La Trobe University), Ashley Huey Yiing Yap(The University of Melbourne), Jason Roberts(The University of Queensland), Kathryn C. Davidson(Australian Regenerative Medicine Institute), Julio M. Carrera(The University of Melbourne), Chee Wah Tan(Duke-NUS Medical School), Chinn Yi Wong(The University of Melbourne), Steven Rockman(CSL (United Kingdom))
Cited by 0
Related Papers
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers
|The Journal of Experimental Medicine|2015|381